Drug Type Small molecule drug |
Synonyms- |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HDAC1 inhibitors(Histone deacetylase 1 inhibitors), HDAC2 inhibitors(Histone deacetylase 2 inhibitors) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H24ClN3O4 |
InChIKeyGTTBEUCJPZQMDZ-UHFFFAOYSA-N |
CAS Registry183319-69-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | - | - |
Not Applicable | Non-Small Cell Lung Cancer Maintenance | 11 | (hrtqzoyjpe) = jdqjzssknz vnylpyiqzy (epuqihxrbk ) View more | - | 17 Oct 2017 |